title: A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
abstract: OBJECTIVE
  ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture and mouse models. This Phase I, open-label, dose-escalation trial of ISIS 14803 was performed in chronic HCV patients.
  
  
  METHODS
  At least 7 days after receiving an initial single dose, twenty-eight patients received 0.5-3 mg/kg ISIS 14803 thrice weekly for 4 weeks by intravenous infusion or subcutaneous injection.
  
  
  RESULTS
  In most patients, the 4-week treatment did not reduce plasma HCV RNA. However, 3 patients receiving > or =2 mg/kg had transient HCV reductions of 1.2-1.7 log(10) that persisted < or =32 days. These reductions were accompanied by asymptomatic, self-resolving elevations in serum alanine transaminase (ALT) levels to >10x the upper limit of normal. Two other patients had ALT flares without plasma HCV reduction. No clinical signs, symptoms of hepatic dysfunction, or laboratory changes in albumin or prothrombin time accompanied ALT elevations.
  
  
  CONCLUSIONS
  ISIS 14803 treatment was associated with HCV reductions in only 3/28 patients. ALT flares in 5 patients also occurred. Further studies to evaluate ISIS 14803 treatment and the mechanisms of the ALT flares are now required.
authors.affiliation: The Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715, USA. mchut001@mc.duke.edu
authors.forename: John G
authors.initials: JG
authors.lastname: McHutchison
authors.forename: Keyur
authors.initials: K
authors.lastname: Patel
authors.forename: Paul
authors.initials: P
authors.lastname: Pockros
authors.forename: Lisa
authors.initials: L
authors.lastname: Nyberg
authors.forename: Stephen
authors.initials: S
authors.lastname: Pianko
authors.forename: Rosie Z
authors.initials: RZ
authors.lastname: Yu
authors.forename: F Andrew
authors.initials: FA
authors.lastname: Dorr
authors.forename: T Jesse
authors.initials: TJ
authors.lastname: Kwoh
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D004333:Drug Administration Routes; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis; D013873:Thionucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy / Q000821:virology
chemical_list: D016376:Oligonucleotides, Antisense; D012367:RNA, Viral; D013873:Thionucleotides; D000410:Alanine Transaminase